Dmitry Kuzmin
Managing Partner @ 4BIO Capital
London, United Kingdom
Dmitry Kuzmin is a Series A investor at 4BIO Capital in London focused on Biotechnology and Health Care. Dmitry Kuzmin - Managing Partner @ 4BIO Capital
- Total investments:
- 8
- Last investment:
- Lead investor:
- 63%
Last updated:
For AI agents: llms.txt
Industries Dmitry Kuzmin invests in
Stages Dmitry Kuzmin invests in
Countries Dmitry Kuzmin invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 5 (63%)
- Health Care 4 (50%)
- Therapeutics 2 (25%)
- Pharmaceutical 2 (25%)
- Genetics 1 (13%)
Stage
- Series A 4 (50%)
- Seed 3 (38%)
- Series B 1 (13%)
Country
- United States 3 (38%)
- United Kingdom 2 (25%)
- Switzerland 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Hornet Therapeutics provides immune cell metabolism & cell therapy for cancer treatment. | $5M / Seed / May 23, 2024 | ||
| Ray Therapeutics is a biotech company developing optogenetic gene therapies for patients with blinding diseases. | $100M / Series A / May 16, 2023 | ||
| Araris Biotech AG (Araris) is a biotechnology start-up company. Their aim is to deliver a breakthrough technology platform that enables the development of next-generation ADC-based safe and potent drugs for various diseases and ailments.They are committed to produce high quality ADCs that do not require any engineering (antibody and/orcell-line) for site-specific conjugation instead the antibodies can directly be taken 'off-the-shelf'. The site-specifically modified ADCs can thus be produced rapidly within a few days and quality control and analysis can be performed quickly with high confidence. Their ADC technology is backed by two patents. | $24M / Series A / Oct 04, 2022 | ||
| Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-basedgene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases. | $75M / Series A / Jun 07, 2022 | ||
| Ray Therapeutics is a biotech company developing optogenetic gene therapies for patients with blinding diseases. | $6M / Seed / Jan 04, 2022 | ||
| Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-basedgene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases. | $10M / Seed / Apr 20, 2021 | ||
| Redpin Therapeutics operates as a preclinical stage gene therapy company. It develops a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system. Its approach integrates powerful principles from synthetic biology, gene therapy, and traditional pharmacotherapy. The company wasfounded in 2017 and is headquartered in New York. | $15.5M / Series A / Mar 25, 2020 | ||
| Orchard Therapeutics is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. Theseprograms include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott Aldrich syndrome) and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline.The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.Orchard is a publicly traded company (NASDAQ: ORTX) with offices in the UK and the US, including London, San Francisco and Boston. | $110M / Series B / Dec 20, 2017 |
Co-Investors
About 4BIO Capital
4BIO Ventures is a London-based firm investing in venture capital and public equities in life sciences. They are focused on advanced therapies addressing high unmet medical and social needs.4BIO Capital Partners is an emerging asset manager focusing on private equity and venture capital in high growth and high return segments of biotech -biologics, gene and cell therapy and bioinformatics.
4BIO Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrew Kozlov
Managing Partner
|
|||
|
Dmitry Kuzmin
Managing Partner
|
|||
Kieran Mudryy
Partner
|
|||
Owen Smith
Principal
|
|||
Vasily Fedorin
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Dmitry Kuzmin invest in?
Dmitry Kuzmin invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Dmitry Kuzmin?
Public channels for Dmitry Kuzmin include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Dmitry Kuzmin last invest?
The most recent investment recorded for Dmitry Kuzmin closed in May 2024. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
